What we didn't know before: the Crohn's idea, that

What we didn't know before: the Crohn's idea, that they could use a capsule that releases the drug at a certain point in the GI tract. It sounds like that technology is further along than I thought. Being able to administer Brilacidin at whatever point is appropriate along the GI tract would make this so much more important for ALL inflammatory diseases of the alimentary canal.

Also my impression was that there were a lot more CDA's signed with Big Pharma than we thought.

And, it's interesting that they've been doing pre-clinical studies on Kevetrin. I don't think we knew that before.